HLS Therapeutics Inc. (TSE:HLS – Get Rating)’s share price reached a new 52-week low during mid-day trading on Friday . The company traded as low as C$4.12 and last traded at C$4.16, with a volume of 1550 shares trading hands. The stock had previously closed at C$4.24.
Analysts Set New Price Targets
A number of research analysts have issued reports on HLS shares. Canaccord Genuity Group dropped their target price on shares of HLS Therapeutics from C$21.75 to C$17.50 in a research report on Friday, March 17th. Stifel Nicolaus lowered their price target on HLS Therapeutics from C$26.00 to C$18.00 in a research note on Friday, March 17th. Finally, Raymond James downgraded shares of HLS Therapeutics from an “outperform” rating to a “market perform” rating and cut their price target for the company from C$24.00 to C$15.00 in a research report on Friday, March 17th.
HLS Therapeutics Stock Performance
The company has a market cap of C$137.49 million, a price-to-earnings ratio of -3.89 and a beta of 0.90. The stock has a 50-day moving average price of C$5.70 and a 200 day moving average price of C$8.08. The company has a debt-to-equity ratio of 77.68, a current ratio of 1.42 and a quick ratio of 1.01.
HLS Therapeutics Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 15th. Shareholders of record on Thursday, June 15th will be given a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 4.71%. The ex-dividend date of this dividend is Thursday, April 27th. HLS Therapeutics’s dividend payout ratio (DPR) is presently -18.35%.
HLS Therapeutics Company Profile
HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular (CV) markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsules; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia.
- Big Lots Becomes A Stomach Churning Value Play
- The Melt-Up In Marvell Is On; But Don’t Chase It Higher
- Is Apple a Growth Stock or a Value Stock?
- Costco’s Earnings Call Reassure Economists, Recession Cancelled
- Hot Inflation, What It Means For The Summer Rally
Receive News & Ratings for HLS Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HLS Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.